Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    Georg Thieme Verlag KG ; 2023
    In:  Angewandte Nuklearmedizin Vol. 46, No. 03 ( 2023-09), p. 215-220
    In: Angewandte Nuklearmedizin, Georg Thieme Verlag KG, Vol. 46, No. 03 ( 2023-09), p. 215-220
    Abstract: Physiologische Anpassungen der Schilddrüsenfunktion in der Schwangerschaft Die Schwangerschaft hat umfangreiche physiologische Auswirkungen auf die Schilddrüse und den Schilddrüsenhormonstoffwechsel. Dies muss bei der Beurteilung der Schilddrüsenlaborparameter unter Beachtung trimenonspezifischer Referenzbereiche sowie bei der Indikationsstellung für den Beginn einer Therapie berücksichtigt werden. Schilddrüsen-Autoantikörper-positive euthyreote Schwangere Die Auswirkungen subklinischer Schilddrüsenfunktionsstörungen und/oder positiver Schilddrüsen-Autoantikörper auf die werdende Mutter sowie den Embryo/Feten werden weiterhin kontrovers diskutiert. Bei euthyreoten Schwangeren mit positiven Schilddrüsen-Autoantikörpern kann eine Levothyroxin (LT4)-Substitution, insbesondere bei Abortrezidiven, diskutiert werden. Subklinische Hypothyreose Die Kombination aus erhöhten Thyreoperoxidase-Antikörpern (TPO-AK) und einer subklinischen Hypothyreose scheint das Risiko für schwangerschaftsassoziierte Komplikationen zu erhöhen, weshalb bei subklinischer Hypothyreose auch unter Berücksichtigung des TPO-AK-Status individuell, jedoch insgesamt großzügig, die Indikation zur LT4-Substitution gestellt wird. Bei einer Substitutionstherapie sollte aber nach der Schwangerschaft die Situation neu evaluiert werden, da viele Mütter keine dauerhafte Schilddrüsenhormongabe benötigen. Manifeste Hypothyreose Die manifeste Hypothyreose ist immer eine klare Indikation für eine rasche LT4-Gabe mit dem Ziel, möglichst zügig eine Euthyreose zu erreichen. Hyperthyreose Die häufig im 1. Trimenon auftretende – physiologische, durch humanes Choriongonadotropin (hCG) vermittelte – passagere Verminderung bis hin zur Suppression des Thyreoidea-stimulierenden Hormons (TSH) stellt keine Indikation für Thyreostatika dar. Bei anderen Formen der manifesten Hyperthyreose muss die Indikation für eine thyreostatische Medikation (Propylthiouracil oder Thionamide) in der Schwangerschaft aufgrund von möglichen teratogenen Effekten sowie der Gefahr der Induktion einer hypothyreoten Stoffwechsellage beim Feten sehr streng sowie trimenonspezifisch gestellt werden und erfordert ein interdisziplinäres Management.
    Type of Medium: Online Resource
    ISSN: 2749-7445 , 2749-7453
    Language: German
    Publisher: Georg Thieme Verlag KG
    Publication Date: 2023
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    In: Cancers, MDPI AG, Vol. 14, No. 14 ( 2022-07-13), p. 3405-
    Abstract: Background: RET (rearranged during transfection) variants are the most prevalent oncogenic events in medullary thyroid cancer (MTC). In advanced disease, multi-tyrosine kinase inhibitors (MKIs) cabozantinib and vandetanib are the approved standard treatment irrespective of RET status. The actual outcome of patients with RET-positive MTC treated with MKIs is ill described. Methods: We here retrospectively determined the RET oncogene variant status with a targeted DNA Custom Panel in a prospectively collected cohort of 48 patients with advanced MTC treated with vandetanib and/or cabozantinib at four German referral centers. Progression-free survival (PFS) and overall survival (OS) probabilities were estimated using the Kaplan-Meier method. Results: In total, 44/48 (92%) patients had germline or somatic RET variants. The M918T variant was found in 29/44 (66%) cases. In total, 2/32 (6%) patients with a somatic RET variant had further somatic variants, while in 1/32 (3%) patient with a germline RET variant, additional variants were found. Only 1/48 (2%) patient had a pathogenic HRAS variant, and no variants were found in 3 cases. In first-line treatment, the median OS was 53 (95% CI (95% confidence interval), 32–NR (not reached); n = 36), and the median PFS was 21 months (12–39; n = 33) in RET-positive MTC patients. In second-line treatment, the median OS was 18 (13–79; n = 22), and the median PFS was 3.5 months (2–14; n = 22) in RET-positive cases. Conclusions: RET variants were highly prevalent in patients with advanced MTC. The treatment results in RET-positive cases were similar to those reported in unselected cohorts.
    Type of Medium: Online Resource
    ISSN: 2072-6694
    Language: English
    Publisher: MDPI AG
    Publication Date: 2022
    detail.hit.zdb_id: 2527080-1
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    In: Cancers, MDPI AG, Vol. 13, No. 2 ( 2021-01-16), p. 317-
    Abstract: Background: The tyrosine kinase inhibitor (TKI) Lenvatinib represents one of the most effective therapeutic options in patients with advanced radioiodine refractory differentiated thyroid carcinoma (DTC). We aimed to assess the role of 2-deoxy-2-[18F] fluoro-D-glucose positron-emission-tomography/computed-tomography (18F-FDG-PET/CT) in the monitoring of functional tumor response compared to morphological response. Methods: In 22 patients, a modified Positron Emission Tomography Response Criteria In Solid Tumors (mPERCIST) evaluation before treatment with Lenvatinib and at 3 and 6 month follow up was performed. Further PET-parameters and morphologic tumor response using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 were assessed and their prediction of progression-free survival (PFS) and disease-specific survival (DSS) was evaluated. Results: Most patients were rated stable in morphological evaluation and progressive using a metabolic response. All patients who responded to therapy through RECIST showed a decline in nearly all Positron Emission Tomography (PET)-parameters. For both time-points, non-responders according to mPERCIST showed significantly lower median PFS and DSS, whereas according to RECIST, only DSS was significantly lower. Conclusion: Tumor response assessment by 18F-FDG-PET outperforms morphological response assessment by CT in patients with advanced radioiodine refractory DTC treated with Lenvatinib, which seems to be correlated with clinical outcomes.
    Type of Medium: Online Resource
    ISSN: 2072-6694
    Language: English
    Publisher: MDPI AG
    Publication Date: 2021
    detail.hit.zdb_id: 2527080-1
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    Online Resource
    Online Resource
    Springer Science and Business Media LLC ; 2023
    In:  Journal of Cancer Research and Clinical Oncology Vol. 149, No. 7 ( 2023-07), p. 3527-3547
    In: Journal of Cancer Research and Clinical Oncology, Springer Science and Business Media LLC, Vol. 149, No. 7 ( 2023-07), p. 3527-3547
    Abstract: Anaplastic thyroid carcinoma (ATC) is an orphan disease with a fatal outcome. Surgery to the primary tumor in metastatic ATC is controversial. Determination of specific surgical techniques may help facilitate local control and, hence, beneficial overall and disease-specific survival. Methods Using individualized patient data derived from our systematic review of literature and our single center study ( n  = 123), conducting a Surveillance, Epidemiology, and End Results register (SEER)-based study ( n  = 617) we evaluated surgery, its combination with systemic and local therapies in metastatic ATC. Results Pooled cohort study showed surgery ( p   〈  0.001), RT ≥ 30 Gy ( p   〈  0.001), ChT ( p   〈  0.001) and multimodal treatment ( p  = 0.014) to result in improved OS univariately. In the multivariate analysis, surgery (1.997 [1.162–3.433], p  = 0.012) and RT ≥ 30 Gy (1.877 [1.232–2.843], p  = 0.012) were independent predictors for OS. In SEER-based study of patients undergoing any tumor-directed treatment ( n  = 445) total thyroidectomy ( p  = 0.031), administration of ChT ( p  = 0.007), RT ( p   〈  0.001), combination of surgery and RT ± ChT ( p   〈  0.001) and multimodal treatment ( p   〈  0.001) correlated with an improved DSS univariately. On the multivariate analysis, debulking surgery was an independent predictor for a worse outcome (HR 0.535, 95%CI 0.332–0.862, p  = 0.010), whereas RT administration correlated with a longer DSS (HR 2.316, 95%CI 1.362–3.939, p = 0.002). Among operated patients from SEER register total thyroidectomy ( p  = 0.031), ChT ( p  = 0.007), RT ( p   〈  0.001), combination of surgery and RT ± ChT ( p   〈  0.001) and multimodal treatment ( p   〈  0.001) correlated with an improved DSS in the univariate analysis, whereas debulking surgery was inversely correlated with the DSS ( p   〈  0.001). On the multivariate analysis, debulking surgery was an independent predictor for a worse DSS (HR 0.535, 95%CI 0.332–0.862, p  = 0.010), whilst RT administration correlated with a longer DSS (HR 2.316, 95%CI 1.362–3.939, p  = 0.002). Conclusions Surgery to the primary tumor with the aim of R0/R1 resection, but not debulking, is associated with a significant OS and DSS benefit even in systemically metastasized disease.
    Type of Medium: Online Resource
    ISSN: 0171-5216 , 1432-1335
    RVK:
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2023
    detail.hit.zdb_id: 1459285-X
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    In: Journal of Cancer Research and Clinical Oncology, Springer Science and Business Media LLC
    Abstract: Pathogenic fusion events involving neurotrophic receptor tyrosine kinase (NTRK) have been described in ~ 2% of differentiated thyroid cancer (DTC). The selective tropomyosin receptor kinase (TRK) inhibitors entrectinib and larotrectinib have been approved in a tumor agnostic manner based on phase 1/2 clinical trials. In a real-world setting at five referral centers, we aimed to describe the prevalence of NTRK gene fusions and the efficacy and safety of TRK inhibitor treatment for non-medullary, advanced thyroid cancer (TC). Methods A total of 184 TC patients with testing for NTRK gene fusions were included. Progression-free survival (PFS) and overall survival (OS) probabilities were estimated using the Kaplan–Meier method in six patients with NTRK fusion-positive TC who underwent TRK inhibitor therapy. Results 8/184 (4%) patients harbored NTRK gene fusions. Six patients with radioiodine (RAI)-refractory TC harboring NTRK1 ( n  = 4) and NTRK3 ( n  = 2) gene fusions were treated with larotrectinib. Five patients (83%) had received ≥ 1 prior systemic therapy and one patient did not receive prior systemic therapy. All patients had morphologically progressive disease before treatment initiation. Objective response rate was 83%, including two complete remissions. Median PFS from start of TRK inhibitor treatment was 23 months (95% confidence interval [CI] , 0–57.4) and median OS was not reached (NR) (95% CI, NR). Adverse events were of grade 1–3. Conclusion The prevalence of NTRK gene fusions in our cohort of RAI-refractory TC is slightly higher than reported for all TC patients. Larotrectinib is an effective treatment option in the majority of NTRK gene fusion-positive advanced TC patients after prior systemic treatment and has a favorable safety profile.
    Type of Medium: Online Resource
    ISSN: 0171-5216 , 1432-1335
    RVK:
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2023
    detail.hit.zdb_id: 1459285-X
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    Online Resource
    Online Resource
    Georg Thieme Verlag KG ; 2022
    In:  TumorDiagnostik & Therapie Vol. 43, No. 06 ( 2022-08), p. 381-385
    In: TumorDiagnostik & Therapie, Georg Thieme Verlag KG, Vol. 43, No. 06 ( 2022-08), p. 381-385
    Type of Medium: Online Resource
    ISSN: 0722-219X , 1439-1279
    RVK:
    Language: German
    Publisher: Georg Thieme Verlag KG
    Publication Date: 2022
    detail.hit.zdb_id: 604664-2
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 7
    Online Resource
    Online Resource
    Georg Thieme Verlag KG ; 2021
    In:  DMW - Deutsche Medizinische Wochenschrift Vol. 146, No. 23 ( 2021-11), p. 1527-1532
    In: DMW - Deutsche Medizinische Wochenschrift, Georg Thieme Verlag KG, Vol. 146, No. 23 ( 2021-11), p. 1527-1532
    Abstract: Diagnose und Prognose Calcitonin ist ein sensitiver und spezifischer Tumormarker zur Früherkennung und Verlaufskontrolle des MTC. Daneben kommt dem Ultraschall der Schilddrüse eine entscheidende Rolle zu. Rolle des RET-Proto-Onkogens Das medulläre Schilddrüsenkarzinom (MTC) nimmt seinen Ursprung aus den parafollikulären Calcitonin-produzierenden C-Zellen. Es macht nur ca. 3–8 % aller Schilddrüsenkarzinome aus. Aktivierende Mutationen im RET (rearranged during transfection)-Gen liegen bei etwa 25 % der Patienten in der Keimbahn vor, werden aber auch beim sporadischen MTC als somatische Mutationen in ca. 60 % der Fälle beobachtet. Bei metastasierter Erkrankung findet sich in 90 % eine RET-Mutation. RET-Mutationen gelten als Treibermutationen und schließen weitere Treibermutationen weitestgehend aus. Seltener sind somatische Mutationen der RAS-Gene. Chirurgische Therapie Die chirurgische Resektion ist bis heute der einzige kurative Therapieansatz. Entscheidend für eine frühzeitige Diagnosestellung ist die Bestimmung des Serum-Calcitonins bei Nachweis von Schilddrüsenknoten. Die chirurgische Therapie steht auch bei der Behandlung lokoregionärer Rezidive oder lokal angehbarer Metastasen im Zentrum. Systemtherapie Bei irresektabel fortgeschrittener und progredienter Erkrankung mit signifikanter Tumorlast kann eine systemische Therapie erforderlich werden. Neuerdings ist die Kenntnis einer RET-Mutation im Tumorgewebe therapeutisch relevant, da mit den selektiven RET-Inhibitoren Selpercatinib und zukünftig Pralsetinib neue, effektive und gut verträgliche Systemtherapien zur Verfügung stehen. Ihr Einsatz ist nach Vortherapie mit einem der Multityrosinkinase-Inhibitoren Vandetanib oder Cabozantinib zugelassen und wird derzeit in der Erstlinientherapie in klinischen Studien untersucht.
    Type of Medium: Online Resource
    ISSN: 0012-0472 , 1439-4413
    RVK:
    RVK:
    Language: German
    Publisher: Georg Thieme Verlag KG
    Publication Date: 2021
    detail.hit.zdb_id: 2035474-5
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 8
    Online Resource
    Online Resource
    Springer Science and Business Media LLC ; 2021
    In:  MMW - Fortschritte der Medizin Vol. 163, No. 17 ( 2021-10), p. 44-49
    In: MMW - Fortschritte der Medizin, Springer Science and Business Media LLC, Vol. 163, No. 17 ( 2021-10), p. 44-49
    Type of Medium: Online Resource
    ISSN: 1438-3276 , 1613-3560
    Language: German
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2021
    detail.hit.zdb_id: 2173071-4
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 9
    In: Journal of Clinical Medicine, MDPI AG, Vol. 9, No. 10 ( 2020-10-09), p. 3231-
    Abstract: Background: The present study aims to evaluate the outcomes and toxicity of elderly anaplastic thyroid cancer (ATC) patients receiving (chemo)radiotherapy, as well as to identify prognostic factors. Patients and methods: A systematic review using the MEDLINE/PubMed and Cochrane databases was performed. Individual data from all eligible studies were extracted, and a pooled analysis (n = 186) was conducted to examine patient characteristics and treatment. All consecutive ATC patients (≥65 years) treated between 2009 and 2019 at our institution were evaluated for outcomes concerning progression-free survival (PFS), overall survival (OS) probabilities and treatment-related toxicity. Results: The systematic review and pooled analysis identified age as a prognostic factor. The median OS of our patient cohort (n = 26) was three months (range = 0–125). The 6-, 12- and 24-month survival rates were 35%, 22% and 11%, respectively. In the univariate analysis, a Karnofsky performance status of 〉 70%, the Union for International Cancer Control Tumor–Node–Metastasis classification, multimodal therapy and an EQD2 of 〉 49 Gy were correlated with longer OS and PFS. The acute grade 3 toxicity of dysphagia, dyspnea, dermatitis, mucositis and dysphonia was found in 23%, 15%, 12%, 12% and 8% of patients. Conclusion: Age appears to be a prognostic factor in ATC. Elderly ATC patients can tolerate multimodal treatment and achieve a promising outcome. Prospective studies need to confirm our findings.
    Type of Medium: Online Resource
    ISSN: 2077-0383
    Language: English
    Publisher: MDPI AG
    Publication Date: 2020
    detail.hit.zdb_id: 2662592-1
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 10
    In: In Vivo, Anticancer Research USA Inc., Vol. 35, No. 1 ( 2021), p. 461-465
    Type of Medium: Online Resource
    ISSN: 0258-851X , 1791-7549
    Language: English
    Publisher: Anticancer Research USA Inc.
    Publication Date: 2021
    detail.hit.zdb_id: 807031-3
    detail.hit.zdb_id: 2492569-X
    SSG: 15,3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages